Advancing RSV Prevention: A New Path Forward

RSV, or respiratory syncytial virus, is a common virus that affects nearly all children by the age of two. Infants and the elderly are at the greatest risk of severe infection. RSV can lead to hospitilisation and life-long health complications.

Innovation in RSV Treatment

Advancements in preventive interventions offer hope in the fight against RSV.

One such innovation is nirsevimab. This long-acting preventive monoclonal antibody reduces the risk of severe RSV in infants by around 80%. It is recommended for infants younger than eight months of age who were born during or are entering their first RSV season.

Immunisation Campaigns in Europe

Evidence of its efficacy inspired European nations to launch RSV immunisation campaigns.

In a joint study, Spanish public health authorities evaluated Galicia’s immunisation campaign and found that it reduced infant hospitalisation rates by close to 90%.

Luxembourg also made a considerable nationwide effort to introduce nirsevimab across hospitals. As a result, the country saw a 69% drop in hospital admissions for infants under 6 months old.

Galicia and Luxembourg are prime examples of how policy that improves access to vaccines and immunisations can lead to better health outcomes.

About RSV

RSV is transmitted through close contact, typically in the winter months. Some infants and young children experience mild cold-like symptoms, while others may develop more severe complications, like pneumonia or bronchiolitis.

While common-sense measures like hand washing can reduce the risk, increasing access to innovative treatments and preventions – whether an immunization, vaccine or maternal vaccine – will improve outcomes for infants and reduce the burden on families.